● Recruiting

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Condition: NSCLC Stage IV · Brain Metastases, Adult · Sponsor: Maastricht University Medical Center

PhasePhase 2

Planned participants25

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Lizza Hendriks, MD, PhD · +31(0)43-3875047 · lizza.hendriks@mumc.nl

Always discuss trial participation with your own doctor first.

Locations (3)

NKI-AvL	Amsterdam, Netherlands	Recruiting
University Medical Center Groningen	Groningen, Netherlands	Recruiting
Maastricht University Medical Center	Maastricht, Netherlands	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06401824